Effective Non-HRT Treatments for Menopausal Hot Flushes

Menopausal hot flushes remain a significant challenge for many women, with hormone replacement therapy (HRT) not effective or suitable for all. Recent reports highlight emerging non-hormonal options and lifestyle approaches that offer relief, including a newly approved medication and evidence-based dietary adjustments. As regulatory bodies evaluate these alternatives, understanding their efficacy and accessibility is crucial for informed decision-making during menopause.

Astellas Pharma’s Veoza (fezolinetant), a non-hormonal treatment targeting the neurokinin-3 receptor to reduce hot flush frequency and severity, has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for use within the NHS in England. This draft guidance, published in April 2026, suggests Veoza could be offered to women experiencing moderate to severe vasomotor symptoms who are unsuitable for or prefer to avoid HRT. The recommendation follows clinical trial data showing statistically significant reductions in hot flush frequency compared to placebo over 12 weeks, positioning Veoza as a potential new option in menopause symptom management.

While Veoza represents a pharmaceutical advance, anecdotal and observational reports continue to highlight the role of diet in managing hot flushes. A personal account featured in the Daily Mail described how eliminating specific dietary triggers — such as caffeine, alcohol, spicy foods, and processed sugars — led to a noticeable reduction in hot flush severity within six weeks after HRT ceased to be effective. The individual reported increased consumption of whole grains, leafy greens, and phytoestrogen-rich foods like soy and flaxseed, alongside consistent hydration and mindful eating practices. Though such experiences are not clinical evidence, they align with broader research suggesting certain dietary patterns may influence vasomotor symptom frequency.

Scientific studies have explored connections between diet and menopausal symptoms, though findings remain mixed. A 2021 review published in the American Journal of Clinical Nutrition analyzed multiple observational studies and found that diets high in fruits, vegetables, and fiber — characteristic of Mediterranean-style eating patterns — were associated with lower reports of hot flushes. Conversely, high intake of saturated fats and sugars showed potential links to increased symptom frequency. However, researchers noted limitations in establishing causality, as most data come from self-reported questionnaires and cannot rule out confounding factors like overall lifestyle, stress levels, or body mass index.

Healthcare providers emphasize that any approach to managing hot flushes should be individualized. The NHS advises women experiencing troubling symptoms to consult their GP to discuss suitability of treatments, which may include HRT, non-hormonal medications like Veoza (subject to local formulary approval), or cognitive behavioural therapy (CBT) — which has demonstrated effectiveness in improving coping strategies and reducing the bother associated with hot flushes, even if frequency does not change significantly. Lifestyle modifications, including regular physical activity, stress reduction techniques, and avoiding known triggers like warm environments or tight clothing, are routinely recommended as first-line supportive measures.

Ongoing research continues to investigate the long-term safety and real-world effectiveness of newer agents like fezolinetant. While initial trials show promise, questions remain about optimal duration of use, potential interactions with other medications, and effects on diverse populations. Similarly, while dietary adjustments carry minimal risk and offer general health benefits, they are not guaranteed to resolve symptoms for everyone. Medical authorities caution against discontinuing prescribed treatments without professional consultation and advise that self-managed approaches should complement, not replace, evidence-based care when symptoms significantly impact quality of life.

As menopause care evolves, the availability of varied options — hormonal, non-hormonal, and lifestyle-focused — allows for more personalized management strategies. The NICE draft guidance on Veoza is subject to consultation, with final publication expected later in 2026. Until then, women are encouraged to engage in open dialogue with healthcare providers about their symptoms, preferences, and medical history to determine the most appropriate and safe approach to navigating this life stage.